KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Assets (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Other Non-Current Assets for 17 consecutive years, with $277.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 10.21% year-over-year to $277.0 million, compared with a TTM value of $277.0 million through Dec 2025, up 10.21%, and an annual FY2025 reading of $277.0 million, up 10.21% over the prior year.
  • Other Non-Current Assets was $277.0 million for Q4 2025 at Biomarin Pharmaceutical, up from $270.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $277.0 million in Q4 2025 and bottomed at $144.7 million in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $201.3 million, with a median of $187.8 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets fell 2.67% in 2023, then soared 46.55% in 2024.
  • Year by year, Other Non-Current Assets stood at $152.1 million in 2021, then grew by 15.85% to $176.2 million in 2022, then fell by 2.67% to $171.5 million in 2023, then skyrocketed by 46.55% to $251.4 million in 2024, then rose by 10.21% to $277.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for BMRN at $277.0 million in Q4 2025, $270.8 million in Q3 2025, and $249.2 million in Q2 2025.